We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Unusual Blood Clots Characterized in Leprosy Patients

By LabMedica International staff writers
Posted on 03 Apr 2018
Leprosy is a chronic infection by Mycobacterium leprae and causes body-wide symptoms, deformities, and disability. More...
It remains a public health problem worldwide, despite the existence of antibiotic combinations that can cure it.

Hemostatic disorders are frequently associated with acute and chronic infections due to the fact that platelet functions, blood coagulation and fibrinolysis are intimately correlated with the immune system. For years, doctors have observed that some patients with leprosy develop unusual blood clots, which can lead to stroke or heart attack.

Scientists at the Oswaldo Cruz Institute (Rio de Janeiro, Brazil) analyzed two groups of patients: a prospective group, which plasma samples were collected before multidrug therapy against leprosy, composed of 11 non-reactional (multibacillary leprosy; MB-NR), being 10 lepromatous leprosy (LL) and one borderline lepromatous (BL). The erythema nodosum leprosum patients group (MB-ENL) included 13 LL and one BL individuals. These two groups include six females, 19 males with median age of 45.2 years, ranging from 23 to 80. The retrospective cohort was composed of 638 leprosy outpatients at an Outpatient Unit, from 2012 to 2014, where 35 patients presented the leprosum clot during serum harvesting.

The team performed SDS-PAGE and protein content was measured with the commercially available 2D Quant-Kit. Spots were taken from the gel, digested with trypsin and analyzed by spectrometry using the MALDI-TOF/TOF 5800. The mass spectrometry protein identifications were obtained with a 5800 Proteomics Analyzer.

The scientists applied the STA-R Evolution instrument to determine partial thromboplastin time (aPPT) and prothrombin time (PT) in all plasma samples. The levels of von Willebrand and soluble tissue factor, C4 complement, and anti-cardiolipin IgM antibody in the serum of leprosy patients were determined using the following commercial kits: Human von Willebrand Factor ELISA kit and Human Tissue Factor ELISA kit and C4 turbiquest, respectively.

The team found that patients both experiencing a reactional episode and those with non-reactional leprosy had factors in their blood, including plasmatic fibrinogen, anti-cardiolipin antibodies, von Willebrand factor, and soluble tissue factor, promoting blood coagulation. Formation of leprosum clots, they showed, was correlated with increased levels of soluble tissue factor and von Willebrand factor. Tests on leprosum clots revealed high contents of lipids and fibrinogen, and showed higher levels of two proteins, complement component 3 and 4 and inter-alpha- trypsin inhibitor family heavy chain-related protein (IHRP), compared to clots from patients without leprosy.

The authors propose that multibacillary patients with high levels of fibrinogen could be beneficiated from a prophylactic use of xanthine derivatives such as pentoxifylline, in order to prevent some of the acute clinical symptoms observed during severe cases of leprosy reactional episodes, such as cyanosis and tissue necrosis, probably related with superficial vein thrombosis. The study was published on March 22, 2018, in the journal PLOS Neglected Tropical Diseases.

Related Links:
Oswaldo Cruz Institute


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.